Edition:
United Kingdom

Aceto Corp (ACET.OQ)

ACET.OQ on NASDAQ Stock Exchange Global Select Market

1.85USD
8:59pm GMT
Change (% chg)

$-0.02 (-1.07%)
Prev Close
$1.87
Open
$1.88
Day's High
$1.92
Day's Low
$1.75
Volume
53,159
Avg. Vol
123,175
52-wk High
$11.98
52-wk Low
$1.53

Latest Key Developments (Source: Significant Developments)

Aceto Reports Q1 Loss Per Share Of $0.59
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Aceto Corp ::ACETO REPORTS FISCAL 2019 FIRST QUARTER RESULTS.Q1 LOSS PER SHARE $0.59.Q1 SALES FELL 11.3 PERCENT TO $164.4 MILLION.CO HAS SUSPENDED GIVING FINANCIAL GUIDANCE DURING ONGOING STRATEGIC REVIEW PERIOD.  Full Article

Aceto Corp Files For Non-Timely 10-K With U.S. SEC
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Aceto Corp ::ACETO CORP FILES FOR NON-TIMELY 10-K WITH U.S. SEC.ACETO CORP SAYS HAS ENCOUNTERED A DELAY IN COMPLETING THE FINANCIAL STATEMENTS FOR THE FISCAL YEAR ENDED JUNE 30, 2018.ACETO - TO SEE WHETHER TO RECORD ADDITIONAL VALUATION ALLOWANCE IN FISCAL YEAR ENDED JUNE 30 REGARDING SOME/ALL OF $76.5 MILLION DOMESTIC NET DEFERRED TAX ASSETS.  Full Article

Aceto Subsidiary Acetris Health Receives Favorable Ruling Regarding Certain Government Contracts
Monday, 16 Jul 2018 

July 16 (Reuters) - Aceto Corp ::ACETO SUBSIDIARY ACETRIS HEALTH RECEIVES FAVORABLE RULING REGARDING CERTAIN GOVERNMENT CONTRACTS.ACETO- COURT DECISION IN ACETRIS HEALTH LLC V. UNITED STATES, INVALIDATING U.S. DEPARTMENT OF VETERANS AFFAIRS INTERPRETATION OF TRADE AGREEMENTS CLAUSE.ACETO CORP - DECISION ALSO IMPACTS ACETRIS' ABILITY TO SUPPLY DOD WITH ITS PRODUCTS.  Full Article

Aceto-With DOJ’S Ongoing Investigation In Marketing, Pricing Practices In Generic Pharma Industry, Co Got Subpoena From U.S. DOJ Antitrust Division
Monday, 23 Apr 2018 

April 23 (Reuters) - Aceto Corp ::ACETO-WITH DOJ’S ONGOING INVESTIGATION IN MARKETING, PRICING PRACTICES IN GENERIC PHARMACEUTICAL INDUSTRY, CO GOT SUBPOENA FROM U.S. DOJ ANTITRUST DIVISION.ACETO CORP SAYS COMPANY IS CURRENTLY PREPARING ITS RESPONSE TO THE SUBPOENA - SEC FILING.  Full Article

Aceto Subsidiary, Rising Pharmaceuticals, Launches Atenolol Tablets, 25Mg, 50Mg And 100Mg
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Aceto Corp ::ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES ATENOLOL TABLETS, 25MG, 50MG AND 100MG.ACETO - UNIT LAUNCHED ATENOLOL TABLETS, 25MG, 50MG AND 100MG, GENERIC VERSION OF TENORMIN FROM ALVOGEN MALTA OPERATIONS.  Full Article

Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Aceto Corp ::ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES EFAVIRENZ CAPSULES, 50MG AND 200MG.SAYS UNIT ‍LAUNCHED GENERIC FOR EFAVIRENZ CAPSULES, AN FDA-APPROVED GENERIC VERSION OF REFERENCE LISTED DRUG SUSTIVA FROM BRISTOL MYERS SQUIBB​.  Full Article

Aceto reports fiscal 2018 first quarter results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Aceto Corp :Aceto reports fiscal 2018 first quarter results.Q1 adjusted non-GAAP earnings per share $0.30.Q1 earnings per share $0.01.Q1 sales $185.3 million versus I/B/E/S view $190.6 million.Q1 earnings per share view $0.29 -- Thomson Reuters I/B/E/S.Sees FY 2018 non-GAAP earnings per share $1.05 to $1.15.Aceto Corp sees ‍fiscal 2018 total revenues to increase approximately 15% to 20%​.Aceto Corp sees ‍fiscal 2018 reported diluted GAAP earnings per share between $0.23 and $0.33​.  Full Article

Aceto corp CFO Douglas Roth notifies co he will retire effective March 31, 2018​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Aceto Corp ::Says on October 26, Douglas Roth, Chief Financial Officer of Aceto Corporation notified company that he will retire effective March 31, 2018​.  Full Article

ACETO appoints William Kennally, III president and CEO
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - ACETO Corp :ACETO appoints William Kennally, III president and CEO.ACETO Corp - ‍Salvatore Guccione, ACETO's chief executive officer has stepped down from all positions with ACETO​.  Full Article